Willow

Decide whether the care proposition earns the price

Willow’s pitch is a continuing relationship with a physician, alongside medication delivery. Its homepage includes doctor messaging and free follow-ups in the program. That can matter to someone who wants questions answered between refills, but it is a service promise rather than a response time I have tested. The case for choosing Willow should rest on that care arrangement and an appropriate prescription, not simply the attractive ease of the intake.

The public semaglutide injection page lists $299 monthly and the tirzepatide injection page $399. At unchanged prices, three months would be $897 or $1,197. Those arithmetic examples make the budget easier to compare, but neither establishes an individual quote or a required three-month purchase. Before joining, ask what the likely ongoing prescription will cost and whether dose changes alter the bill.

A shopper satisfied with a less expensive service elsewhere should identify what Willow adds that they will actually use. Access has value when the prescribing team is reachable and follows the case; paying more alone is no assurance of better clinical outcomes.

The monthly amount can change with the prescription

The FAQ says the program starts at $299 and that medication costs vary by dosage and prescription. The terms also allow the subscription fee to change when the prescription or refill frequency changes, with disclosure and any required consent. An entry price therefore needs a second question: what would the charge be under the clinician’s proposed next stage?

Ask for the medication, amount supplied, supply period and recurring charge together. Comparing only the name of the molecule misses whether the quoted purchase covers the same time. Keep the order summary and the accepted billing interval, particularly if a campaign takes you into a different enrollment flow.

Willow says insurance is unnecessary, and its terms state that it does not submit reimbursement claims to third-party payors. Someone expecting an insurance-covered brand prescription should compare that pathway separately before paying for this cash-pay program. The ability to enter an HSA or FSA card is not an insurance coverage determination.

Tablets change the evidence question

Willow advertises both injections and sublingual tablets. Its tirzepatide tablet page lists $399 monthly and describes a daily preparation dissolving under the tongue. The same page identifies it as compounded and says it is not FDA-approved. This is a real advertised format choice, but it should not be treated as an interchangeable version of a brand injection.

For someone avoiding needles, I would ask the prescriber what evidence supports the exact preparation, how success will be assessed and what happens if it does not help. The convenience of a daily tablet answers the administration question; it does not settle absorption, clinical effectiveness or equivalence. This research did not establish a clinical trial of Willow’s particular tablet.

FDA recommends compounded GLP-1 drugs only for patients whose needs cannot be met by an approved medicine, with a prescription filled by a state-licensed pharmacy. Compounded drugs do not receive FDA premarket review for safety, effectiveness and quality. Ask the clinician to explain the reason for compounding in your case.

Check the practice and pharmacy behind the brand

The medical consent names Willow Medical of California, P.C., and distinguishes the medical practice from Willow Health Services, the technology platform. That gives a prospective patient a useful entity to ask about. It does not identify the professional who would personally review your case or independently verify their license.

The product pages describe state-licensed U.S. pharmacy partners without establishing my assigned dispensing pharmacy. Request the pharmacy’s legal name, location and contact details before committing, and confirm that it can dispense your prescribed preparation to your state. A brand on a pictured vial cannot answer those questions.

Coverage also needs an individual check. The consent’s two state lists are not identical, including a difference concerning Wyoming, while product disclosures say availability varies by state. I would use the actual location and selected preparation to obtain confirmation rather than infer nationwide availability from a fully online service.

Separate assessment speed from delivery speed

The FAQ describes a same-day assessment, but also allows two to four business days for pharmacy processing after prescribing and another two to three days for delivery. Its two-day shipping language is therefore not a promise of medication at your door two days after starting intake. Build the pharmacy stage into any transfer plan.

The FAQ says patients typically see the same physician, with exceptions for vacations and staff changes. That continuity is a useful reason to shortlist Willow. Before relying on it, ask who covers a medication concern during an absence and whether the advertised around-the-clock care team includes a prescribing clinician at the time you need one.

The FAQ currently excludes people with diabetes. If that applies to you, seek a program prepared to manage that condition instead of assuming a GLP-1 storefront accepts every patient using these medicines. Eligibility remains a clinician’s decision even when a preliminary assessment looks favorable.

Cancel before the pharmacy handoff

Willow’s FAQ instructs patients to message the care team at least two business days before the next processing date. It describes a full refund when cancellation occurs before the prescription is sent to the pharmacy. The terms also refer to account cancellation and separate subscription and return policies. Obtain the applicable instructions and next processing date for your order.

My recommendation is conditional: Willow makes sense when you value the continuing physician relationship, can verify the dispensing arrangement and accept the full price at your proposed dose. I would resolve those points before enrolling, and discuss compounded tablets particularly carefully. This assessment uses public pages checked October 25, 2026; it includes no enrollment, medication use, shipment test or firsthand support interaction.